United Therapeuticsvs.Vertex Pharmaceuticals
UTHR vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 5.2× larger than United Therapeutics by market cap; United Therapeutics trades at the lower P/E (18.0 vs 27.9); year to date, United Therapeutics leads (+12.3% vs +7.1%).
Side by side
| UTHR | VRTX | |
|---|---|---|
| Market cap | $23.2B | $121B |
| Price | $547.06 | $485.39 |
| Today | −1.0% | −2.2% |
| Return YTD | +12.3% | +7.1% |
| Return 1Y | +82.3% | +1.2% |
| P/E | 18.0 | 27.9 |
| P/S | 7.3 | 9.9 |
| P/B | 3.9 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
United TherapeuticsUTHR
Biopharma in pulmonary hypertension and organ manufacturing (xenotransplantation).
Full UTHR profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where UTHR and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →